PPAR/PGC-1 regulation of metabolism in cardiac disease

Translational Cardiology: Molecular Basis of Cardiac Metabolism, Cardiac Remodeling, Translational Therapies and Imaging Techniques

Volumn , Issue , 2012, Pages 83-111

  Duncan, Jennifer G ^a   Finck, Brian N ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIAC DISEASE;

EID: 84959262927     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-61779-891-7_4     Document Type: Chapter

References (149)

1. Chung S, Arrell DK, Faustino RS, Terzic A, Dzeja PP. Glycolytic network restructuring integral to the energetics of embryonic stem cell cardiac differentiation. J Mol Cell Cardiol. 2010;48:725-34.
2. Chung S, Dzeja PP, Faustino RS, Perez-Terzic C, Behfar A, Terzic A. Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat Clin Pract Cardiovasc Med. 2007;4 Suppl 1:S60-7.
3. St John JC, Ramalho-Santos J, Gray HL, Petrosko P, Rawe VY, Navara CS, Simerly CR, Schatten GP. The expression of mitochondrial DNA transcription factors during early cardiomyocyte in vitro differentiation from human embryonic stem cells. Cloning Stem Cells. 2005;7:141-53.
4. Lopaschuk GD, Jaswal JS. Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J Cardiovasc Pharmacol. 2010;56: 130-40.
5. Schaffer JE, Lodish HF. Expression cloning and characterization of a novel adipocyte longchain fatty acid transport protein. Cell. 1994;79:427-36.
6. Abumrad NA, el-Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiaion. Homology with human cd36. J Biol Chem. 1993;268: 17665-8.
7. Binas B, Danneberg H, McWhir J, Mullins L, Clark AJ. Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization. FASEB J. 1999;13:805-12.
8. Banke NH, Wende AR, Leone TC, O'Donnell JM, Abel ED, Kelly DP, Lewandowski ED. Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor pparalpha. Circ Res. 2010;107:233-41.
9. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, Heldmaier G, Maier R, Theussl C, Eder S, Kratky D, Wagner EF, Klingenspor M, Hoefler G, Zechner R. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science. 2006;312:734-7.
10. Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase i gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem. 1998;273:23786-92.
11. Brown NF, Weis BC, Husti JE, Foster DW, McGarry JD. Mitochondrial carnitine palmitoyltransferase i isoform switching in the developing rat heart. J Biol Chem. 1995; 270:8952-7.
12. Mascar C, Acosta E, Ortiz JA, Marrero PF, Hegardt FG, Haro D. Control of human muscletype carnitine palmitoyltransferase i gene transcription by peroxisome proliferator-activated receptor . J Biol Chem. 1998;273:8560-3.
13. Steffen ML, Harrison WR, Elder FF, Cook GA, Park EA. Expression of the rat liver carnitine palmitoyltransferase i (cpt-i a) gene is regulated by sp1 and nuclear factor y: chromosomal localization and promoter characterization. Biochem J. 1999;340:425-32.
14. Yu GS, Lu YC, Gulick T. Co-regulation of tissue-speci fi c alternative human carnitine palmitoyltransferase i gene promoters by fatty acid enzyme substrate. J Biol Chem. 1998;273: 32901-9.
15. McGarry JD, Woeltje KF, Kuwajima M, Foster DW. Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. Diabetes Metab Rev. 1989;5:271-84.
16. Kelly DP, Strauss AW. Inherited cardiomyopathies. N Engl J Med. 1994;330:913-9.
17. Fayssoil A. Heart diseases in mitochondrial encephalomyopathy, lactic acidosis, and stroke syndrome. Congest Heart Fail. 2009;15:284-7.
18. Hill MR, Clarke S, Rodgers K, Thornhill B, Peters JM, Gonzalez FJ, Gimble JM. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect Immun. 1999;67:3488-93.
19. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (ppars): nuclear receptors at the crossroads between lipid metabolism and in fl ammation. In fl amm Res. 2000;49:497-505.
20. Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V. Dello Russo C. Receptor-independent actions of ppar thiazolidinedione agonists: Is mitochondrial function the key? Biochem Pharmacol. 2005;70:177-88.
21. Vega RB, Huss JM, Kelly DP. The coactivator pgc-1 cooperates with peroxisome proliferator- activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol. 2000;20:1868-76.
22. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1998;92:829-39.
23. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645-50.
24. Cook WS, Yeldandi AV, Rao MS, Hashimoto T, Reddy JK. Less extrahepatic induction of fatty acid beta-oxidation enzymes by ppar alpha. Biochem Biophys Res Commun. 2000;278: 250-7.
25. Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andreassen M, Larsen TS. Cardiac function and metabolism in type 2 diabetic mice after treatment with bm 17.0744, a novel ppar-alpha activator. Am J Physiol Heart Circ Physiol. 2002;283:H949-57.
26. Aasum E, Cooper M, Severson DL, Larsen TS. Effect of bm 17.0744, a pparalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. Can J Physiol Pharmacol. 2005;83:183-90.
27. Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, Courtois MR, Lavine KJ, Goldberg IJ, Kelly DP. Rescue of cardiomyopathy in peroxisome proliferator-activated receptoralpha transgenic mice by deletion of lipoprotein lipase identi fi es sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators. Circulation. 2010;121:426-35.
28. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J. Activation of peroxisome proliferator- activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA. 2003;100:15924-9.
29. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-71.
30. Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, van Bilsen M. Peroxisome proliferator-activated receptor (ppar) alpha and pparbeta/ delta, but not ppargamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res. 2003;92:518-24.
31. Caglayan E, Stauber B, Collins AR, Lyon CJ, Yin F, Liu J, Rosenkranz S, Erdmann E, Peterson LE, Ross RS, Tangirala RK, Hsueh WA. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fi brosis. Diabetes. 2008;57:2470-9.
32. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (pparalpha) in the cellular fasting response: the pparalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA. 1999;96:7473-8.
33. Panagia M, Gibbons GF, Radda GK, Clarke K. Ppar-alpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am J Physiol Heart Circ Physiol. 2005;288:H2677-83.
34. Sambandam N, Morabito D, Wagg C, Finck BN, Kelly DP, Lopaschuk GD. Chronic activation of pparalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol. 2006;290:H87-95.
35. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD, Severson DL, Kelly DP, Lopaschuk GD. A role for peroxisome proliferator-activated receptor alpha (pparalpha) in the control of cardiac malonyl-coa levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking pparalpha are associated with higher concentrations of malonyl-coa and reduced expression of malonyl-coa decarboxylase. J Biol Chem. 2002;277:4098-103.
36. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, Ono T, Hasegawa G, Naito M, Nakajima T, Kamijo Y, Gonzalez FJ, Aoyama T. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem. 2000;275:22293-9.
37. Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, Tian R. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation. 2005;112:2339-46.
38. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE, Yang Q. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med. 2004;10:1245-50.
39. Wang P, Liu J, Li Y, Wu S, Luo J, Yang H, Subbiah R, Chatham J, Zhelyabovska O, Yang Q. Peroxisome proliferator-activated receptor delta is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart. Circ Res. 2010;106:911-9.
40. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM. Ppar gamma is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999;4:585-95.
41. Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM. Cardiomyocytespeci fi c knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res. 2005;97:372-9.
42. Ding G, Fu M, Qin Q, Lewis W, Kim HW, Fukai T, Bacanamwo M, Chen YE, Schneider MD, Mangelsdorf DJ, Evans RM, Yang Q. Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage. Cardiovasc Res. 2007;76:269-79.
43. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor alpha (pparalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol. 2002;34:1249-57.
44. Harris IS, Treskov I, Rowley MW, Heximer S, Kaltenbronn K, Finck BN, Gross RW, Kelly DP, Blumer KJ, Muslin AJ. G-protein signaling participates in the development of diabetic cardiomyopathy. Diabetes. 2004;53:3082-90.
45. Park SY, Cho YR, Finck BN, Kim HJ, Higashimori T, Hong EG, Lee MK, Danton C, Deshmukh S, Cline GW, Wu JJ, Bennett AM, Rothermel B, Kalinowski A, Russell KS, Kim YB, Kelly DP, Kim JK. Cardiac-speci fi c overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes. 2005;54:2514-24.
46. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, Febbraio M, Finck BN, Kelly DP. Cd36 de fi ciency rescues lipotoxic cardiomyopathy. Circ Res. 2007;100:1208-17.
47. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. A critical role for pparalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA. 2003;100:1226-31.
48. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptoralpha/ pgc-1alpha gene regulatory pathway. Circulation. 2007;115:909-17.
49. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by pparalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002;109:121-30.
50. Burkart EM, Sambandam N, Han X, Gross RW, Courtois M, Gierasch CM, Shoghi K, Welch MJ, Kelly DP. Nuclear receptors pparbeta/delta and pparalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest. 2007;117:3930-9.
51. Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ. Cardiomyocyte expression of ppargamma leads to cardiac dysfunction in mice. J Clin Invest. 2007;117:2791-801.
52. Son NH, Yu S, Tuinei J, Arai K, Hamai H, Homma S, Shulman GI, Abel ED, Goldberg IJ. Ppargamma-induced cardiolipotoxicity in mice is ameliorated by pparalpha de fi ciency despite increases in fatty acid oxidation. J Clin Invest. 2010;120:3443-54.
53. Lin J, Puigserver P, Donovan J, Tarr P, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1beta (pgc-1beta), a novel pgc-1-related transcription coactivator associated with host cell factor. J Biol Chem. 2002;277:1645-8.
54. Andersson U, Scarpulla RC. Pgc-1-related coactivator, a novel, serum-inducible coactivator of nuclear respiratory factor 1-dependent transcription in mammalian cells. Mol Cell Biol. 2001;21:3738-49.
55. Lai L, Leone TC, Zechner C, Schaeffer PJ, Kelly SM, Flanagan DP, Medeiros DM, Kovacs A, Kelly DP. Transcriptional coactivators pgc-1alpha and pgc-lbeta control overlapping programs required for perinatal maturation of the heart. Genes Dev. 2008;22:1948-61.
56. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator- activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000;106:847-56.
57. Wallberg AE, Yamamura S, Malik S, Spiegelman BM, Roeder RG. Coordination of p300- mediated chromatin remodeling and trap/mediator function through coactivator pgc-1alpha. Mol Cell. 2003;12:1137-49.
58. Roeder RG. Transcriptional regulation and the role of diverse coactivators in animal cells. FEBS Lett. 2005;579:909-15.
59. Puigserver P, Adelmant G, Wu Z, Fan M, Xu J, O'Malley B, Spiegelman BM. Activation of ppargamma coactivator-1 through transcription factor docking. Science. 1999;286:1368-71.
60. Sano M, Izumi Y, Helenius K, Asakura M, Rossi DJ, Xie M, Taffet G, Hu L, Pautler RG, Wilson CR, Boudina S, Abel ED, Taegtmeyer H, Scaglia F, Graham BH, Kralli A, Shimizu N, Tanaka H, Makela TP, Schneider MD. Menage-a-trois 1 is critical for the transcriptional function of ppargamma coactivator 1. Cell Metab. 2007;5:129-42.
61. Monsalve M, Wu Z, Adelmant G, Puigserver P, Fan M, Spiegelman BM. Direct coupling of transcription and mrna processing through the thermogenic coactivator pgc-1. Mol Cell. 2000;6:307-16.
62. Lin J, Handschin C, Spiegelman BM. Metabolic control through the pgc-1 family of transcription coactivators. Cell Metab. 2005;1:361-70.
63. Finck BN, Kelly DP. Pgc-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006;116:615-22.
64. Huss JM, Kopp RP, Kelly DP. Peroxisome proliferator-activated receptor coactivator-1alpha (pgc-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma. Identi fi cation of novel leucine-rich interaction motif within pgc-1alpha. J Biol Chem. 2002;277:40265-74.
65. Schreiber SN, Knutti D, Brogli K, Uhlmann T, Kralli A. The transcriptional coactivator pgc-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor alpha (erralpha). J Biol Chem. 2003;278:9013-8.
66. Huss JM, Torra IP, Staels B, Giguere V, Kelly DP. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol. 2004;24:9079-91.
67. Dufour CR, Wilson BJ, Huss JM, Kelly DP, Alaynick WA, Downes M, Evans RM, Blanchette M, Giguere V. Genome-wide orchestration of cardiac functions by the orphan nuclear receptors erralpha and gamma. Cell Metab. 2007;5:345-56.
68. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator pgc-1. Cell. 1999;98:115-24.
69. Scarpulla RC. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. Biochim Biophys Acta. 2002;1576:1-14.
70. Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 2004;18:357-68.
71. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res. 2004;95: 68-78.
72. Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest. 2005;115:547-55.
73. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP. Pgc-1alpha de fi ciency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 2005;3:e101.
74. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM. Transverse aortic constriction leads to accelerated heart failure in mice lacking ppar-gamma coactivator 1alpha. Proc Natl Acad Sci USA. 2006;103:10086-91.
75. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, Ahmad F, Matsui T, Chin S, Wu PH, Rybkin II, Shelton JM, Manieri M, Cinti S, Schoen FJ, Bassel-Duby R, Rosenzweig A, Ingwall JS, Spiegelman BM. Transcriptional coactivator pgc-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab. 2005;1:259-71.
76. Lelliott CJ, Medina-Gomez G, Petrovic N, Kis A, Feldmann HM, Bjursell M, Parker N, Curtis K, Campbell M, Hu P, Zhang D, Litwin SE, Zaha VG, Fountain KT, Boudina S, Jimenez-Linan M, Blount M, Lopez M, Meirhaeghe A, Bohlooly YM, Storlien L, Stromstedt M, Snaith M, Oresic M, Abel ED, Cannon B, Vidal-Puig A. Ablation of pgc-1beta results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. PLoS Biol. 2006;4:e369.
77. Sonoda J, Mehl IR, Chong LW, Nofsinger RR, Evans RM. Pgc-1beta controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosis. Proc Natl Acad Sci USA. 2007;104:5223-8.
78. Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, Saffitz JE, Medeiros DM, Valencik ML, McDonald JA, Kelly DP. Cardiac-speci fi c induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res. 2004;94:525-33.
79. Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to atp production in hypertrophied hearts. Am J Physiol. 1994;267:H742-50.
80. Christe MD, Rodgers RL. Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat. J Mol Cell Cardiol. 1994;26:1371-5.
81. Massie BM, Schaefer S, Garcia J, McKirnan MD, Schwartz GG, Wisneski JA, Weiner MW, White FC. Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy. Circulation. 1995;91:1814-23.
82. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension. 1988;11:416-26.
83. Dewald O, Sharma S, Adrogue J, Salazar R, Duerr GD, Crapo JD, Entman ML, Taegtmeyer H. Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation. 2005;112:407-15.
84. Huss JM, Levy FH, Kelly DP. Hypoxia inhibits the peroxisome proliferator-activated receptor alpha/retinoid x receptor gene regulatory pathway in cardiac myocytes: a mechanism for o2-dependent modulation of mitochondrial fatty acid oxidation. J Biol Chem. 2001;276: 27605-12.
85. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the in fl ammatory process in patients with ischaemic dilated cardiomyopathy. Heart. 2005;91:161-5.
86. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, Ashrafian H, Horowitz J, Fraser AG, Clarke K, Frenneaux M. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 2005;112:3280-8.
87. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, Volterrani M, Rosano GM. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J. 2004;25:1814-21.
88. Tabernero A, Schoonjans K, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R. Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol. 2002;2:10.
89. Tian Q, Grzemski FA, Panagiotopoulos S, Ahokas JT. Peroxisome proliferator-activated receptor alpha agonist, clo fi brate, has profound in fl uence on myocardial fatty acid composition. Chem Biol Interact. 2006;160:241-51.
90. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C. Ligands of the peroxisome proliferator-activated receptors (ppargamma and ppar-alpha) reduce myocardial infarct size. FASEB J. 2002;16:1027-40.
91. Yue TL, Nerurkar SS, Bao W, Jucker BM, Sarov-Blat L, Steplewski K, Ohlstein EH, Willette RN. In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in zucker fatty rats. J Pharmacol Exp Ther. 2008;325: 466-74.
92. Lygate CA, Hulbert K, Monfared M, Cole MA, Clarke K, Neubauer S. The ppar g-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res. 2003;58:632-7.
93. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res. 2004;62:135-44.
94. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. The prospective pioglitazone clinical trial in macrovascular events (proactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004;27:1647-53.
95. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet. 2005;366:1279-89.
96. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 1996;94:2837-42.
97. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated receptor- α during cardiac hypertrophic growth. J Clin Invest. 2000;105:1723-30.
98. Takeyama D, Kagaya Y, Yamane Y, Shiba N, Chida M, Takahashi T, Ido T, Ishide N, Takishima T. Effects of chronic right ventricular pressure overload on myocardial glucose and free fatty acid metabolism in the conscious rat. Cardiovasc Res. 1995;29:763-7.
99. Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:271-7.
100. Sack MN, Disch DL, Rockman HA, Kelly DP. A role for sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. Proc Natl Acad Sci USA. 1997;94: 6438-43.
101. Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC, Vazquez-Carrera M. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;65:832-41.
102. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation. 2001;104:2923-31.
103. Sihag S, Cresci S, Li AY, Sucharov CC, Lehman JJ. Pgc-1alpha and erralpha target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol. 2009;46:201-12.
104. Arany Z, Lebrasseur N, Morris C, Smith E, Yang W, Ma Y, Chin S, Spiegelman BM. The transcriptional coactivator pgc-1drives the formation of oxidative type iix fi bers in skeletal muscle. Cell Metab. 2007;5:35-46.
105. Frey N, Olson EN. Modulating cardiac hypertrophy by manipulating myocardial lipid metabolism? Circulation. 2002;105:1152-4.
106. Young ME, Laws FA, Goodwin GW, Taegtmeyer H. Reactivation of peroxisome proliferatoractivated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem. 2001;276:44390-5.
107. Brigadeau F, Gele P, Wibaux M, Marquie C, Martin-Nizard F, Torpier G, Fruchart JC, Staels B, Duriez P, Lacroix D. The pparalpha activator feno fi brate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy. J Cardiovasc Pharmacol. 2007;49:408-15.
108. Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G, Yamada A, Kato T, Izawa H, Murohara T, Yokota M. Attenuation of cardiac dysfunction by a ppar-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol. 2006;41:318-29.
109. Liang F, Wang F, Zhang S, Gardner DG. Peroxisome proliferators activated receptor (ppar) a agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology. 2003;144:4187-94.
110. Bottomley PA, Wu KC, Gerstenblith G, Schulman SP, Steinberg A, Weiss RG. Reduced myocardial creatine kinase fl ux in human myocardial infarction: an in vivo phosphorus magnetic resonance spectroscopy study. Circulation. 2009;119:1918-24.
111. Gupta A, Chacko VP, Weiss RG. Abnormal energetics and atp depletion in pressure-overload mouse hearts: in vivo high-energy phosphate concentration measures by noninvasive magnetic resonance. Am J Physiol Heart Circ Physiol. 2009;297:H59-64.
112. Ingwall JS, Kramer MF, Fifer MA, Lorell BH, Shemin R, Grossman W, Allen PD. The creatine kinase system in normal and diseased human myocardium. N Engl J Med. 1985;313:1050-4.
113. Schilling J, Kelly DP. The pgc-1 cascade as a therapeutic target for heart failure. J Mol Cell Cardiol. 2011;51(4):578-83.
114. Cohen-Solal A, Beauvais F, Logeart D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail. 2008;14:615-25.
115. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the framingham study. J Am Coll Cardiol. 1993;22:6A-13.
116. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the framingham study. Am J Cardiol. 1974;34:29-34.
117. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care. 2003;26:2433-41.
118. Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Prog Cardiovasc Dis. 1985;4:255-70.
119. Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol. 1995;27:169-79.
120. Rodrigues B, McNeill JH. The diabetic heart: metabolic causes for the development of cardiomyopathy. Cardiovasc Res. 1992;26:913-22.
121. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res. 1997;34:25-33.
122. Murthy VK, Shipp JC. Regulation of heart triglyceride synthesis in diabetes. Adv Myocardiol. 1980;2:71-9.
123. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004;18:1692-700.
124. Szczepaniak LS, Victor RG, Orci L, Unger RH. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in america. Circ Res. 2007;101:759-67.
125. Mitra R, Nogee DP, Zechner JF, Yea K, Gierasch CM, Kovacs A, Medeiros DM, Kelly DP, Duncan JG. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/22080103" The transcriptional coactivators, PGC-1a and β, cooperate to maintain cardiac mitochondrial function during the early stages of insulin resistance. J Mol Cell Cardiol. 2012;52(3):701-10.
126. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Jeong Yun U, Cooksey RC, Litwin SE, Abel ED. Reduced cardiac ef fi ciency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology. 2005;146:5341-9.
127. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS. Cardiac steatosis in diabetes mellitus: a 1 h-magnetic resonance spectroscopy study. Circulation. 2007;116:1170-5.
128. Paulson DJ, Crass MF. Endogenous triacylglycerol metabolism in diabetic heart. Am J Physiol. 1982;242:H1084-94.
129. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human disease. Proc Natl Acad Sci USA. 2000;97:1784-9.
130. Kuo TH, Moore KH, Giacomelli F, Wiener J. Defective oxidative metabolism of heart mitochondria from genetically diabetic mice. Diabetes. 1983;32:781-7.
131. Shen X, Zheng S, Thongboonkerd V, Xu M, Pierce Jr WM, Klein JB, Epstein PN. Cardiac mitochondrial damage and biogenesis in a chronic model of type i diabetes. Am J Physiol Endocrinol Metab. 2004;287:E896-905.
132. Boudina S, Sena S, O'Neill BT, Tathireddy P, Young ME, Abel ED. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation. 2005;112:2686-95.
133. Andrulionyte L, Zacharova J, Chiasson JL, Laakso M. Common polymorphisms of the ppar- g 2 (pro12a1a) and pgc-1 a (gly482ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the stop-niddm trial. Diabetologia. 2004;47:2176-84.
134. Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O. Mutation analysis of peroxisome proliferator-activated receptor- γ coactivator-1 (pgc-1) and relationships of identi fi ed amino acid polymorphisms to type ii diabetes mellitus. Diabetologia. 2001;44:2220-6.
135. Flavell DM, Torra IP, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE. Variation in the ppar a gene is associated with altered function in vitro and plasma lipid concentrations in type ii diabetic subjects. Diabetologia. 2000;43:673-80.
136. Tai ES, Corella D, Demissie S, Cupples LA, Coltell O, Schaefer EJ, Tucker KL, Ordovas JM. Polyunsaturated fatty acids interact with the ppara-l162v polymorphism to affect plasma triglyceride and apolipoprotein c-iii concentrations in the framingham heart study. J Nutr. 2005;135:397-403.
137. Shin HD, Park BL, Kim LH, Jung HS, Cho YM, Moon MK, Park YJ, Lee HK, Park KS. Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity. Diabetes. 2004;53:847-51.
138. Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E. Evidence that peroxisome proliferator-activated receptor delta in fl uences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol. 2003;23:637-43.
139. Jamshidi Y, Montgomery HE, Hense HW, Myerson SG, Torra IP, Staels B, World MJ, Doering A, Erdmann J, Hengstenberg C, Humphries SE, Schunkert H, Flavell DM. The ppar a gene regulates left ventricular growth in response to exercise and hypertension. Circulation. 2002;105:950-5.
140. Cresci S, Huss JM, Beitelshees AL, Jones PG, Minton MR, Dorn GW, Kelly DP, Spertus JA, McLeod HL. A pparalpha promoter variant impairs err-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes. PLoS One. 2010;5:e12584.
141. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A pro12ala substitution in ppargamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284-7.
142. Chuang LM, Hsiung CA, Chen YD, Ho LT, Sheu WH, Pei D, Nakatsuka CH, Cox D, Pratt RE, Lei HH, Tai TY. Sibling-based association study of the ppargamma2 pro12ala polymorphism and metabolic variables in chinese and japanese hypertension families: a sapphire study. Stanford asian-paci fi c program in hypertension and insulin resistance. J Mol Med. 2001;79:656-64.
143. Doney AS, Fischer B, Leese G, Morris AD, Palmer CN. Cardiovascular risk in type 2 diabetes is associated with variation at the pparg locus: a go-darts study. Arterioscler Thromb Vasc Biol. 2004;24:2403-7.
144. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, Zee RY. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (pparg2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol. 2003;23:859-63.
145. Wang S, Fu C, Wang H, Shi Y, Xu X, Chen J, Song X, Sun K, Wang J, Fan X, Yang X, Huan T, Hi R. Polymorphisms of the peroxisome proliferator-activated receptor- γ coactivator-1 a gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy. Clin Chem Lab Med. 2007;45:962-7.
146. Tai ES, Collins D, Robins SJ, O'Connor Jr JJ, Bloomfield HE, Ordovas JM, Schaefer EJ, Brousseau ME. The l162v polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the veterans affairs hdl intervention trial (va-hit). Atherosclerosis. 2006;187: 153-60.
147. Cresci S. Pharmacogenetics of the ppar genes and cardiovascular disease. Pharmacogenomics. 2007;8:1581-95.
148. Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M. Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (ppara) in fl uence the conversion from impaired glucose tolerance to type 2 diabetes: the stop-niddm trial. Diabetes. 2007;56:1181-6.
149. Cresci S, Jones PG, Sucharov CC, Marsh S, Lanfear DE, Garsa A, Courtois M, Weinheimer CJ, Wu J, Province MA, Kelly DP, McLeod HL, Spertus JA. Interaction between ppara genotype and beta-blocker treatment in fl uences clinical outcomes following acute coronary syndromes. Pharmacogenomics. 2008;9:1403-17.